Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Apollon logo — The wearable that reads your glucose

Apollon

The wearable that reads your glucose

Founded 2021 Korea South Korea South 40 employees Seed Total: $2.30B Biotechnology, Health Care +3

General Information

Company Name Apollon
Founded Year 2021
Location Korea South Korea South +2
Founders / Decision Makers
Team member
Employees 40
Industries Biotechnology, Health Care, Medical Devices +2
Funding Stage Seed
Social

Get notified when Apollon moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
1 month ago

Apollon is strategically fortifying its clinical expertise with the appointment of Dr. Medha Munshi to its Advisory Board, a critical move for guiding clinical strategy and evidence generation as they progress through trials. This significant team strengthening, coupled with their active solicitation of fundraising advice, strongly indicates the company is preparing for an upcoming capital raise to support its continued development and validation efforts.

Signal Types
Hiring Funding
Strategic Labels
Clinical Strategy Team Strengthening Fundraising Preparation
Next Move: Fundraising
·
Impact: 8/10
·
Ideal For: Early-stage MedTech & Deep Tech VCs – Series A

About Apollon

Apollon, founded in 2021, is revolutionizing diabetes management with Moglu, a pioneering wearable that continuously reads glucose through the skin without needles, patches, or consumables. This innovative device leverages Raman spectroscopy, developed alongside MIT, and is currently undergoing clinical trials at a Harvard-affiliated hospital. Based in both Boston and Seoul, the company is positioned at the intersection of Biotechnology, Health Care, Medical Devices, and cutting-edge Sensor Tech and Machine Learning.

Apollon’s headquarters in South Korea provides strategic access to key markets in Asia and beyond. The company's recent Seed investment of KRW2.30B, closed on April 1, 2024, saw participation from prominent investors including KB Investments, BeHigh Investment, STIC Ventures, and Mirae Science and Technology. This funding underscores strong market confidence in Apollon's potential to transform diabetes care.

Taxonomy: wearable technology, glucose monitoring, diabetes management, non-invasive medical devices, Raman spectroscopy, medical technology innovation, biomedical engineering, clinical trials, MIT collaboration, Harvard-affiliated research, medical device startup, continuous monitoring technology

Services & Products

Development of needle-free continuous glucose monitors
Research and innovation in Raman-based glucose sensing
Integration of optical engineering in wearable medical devices

Target Customers

Individuals with diabetes Healthcare professionals Medical institutions Patients seeking non-invasive monitoring solutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed •••••• 4
Investor Investor
•••• •••• 		01 Apr 2024
Seed •••••• 1
Investor
01 Aug 2023

Apollon Alternatives & Competitors

View All Alternatives
Apollon vs
GlucoSet
GlucoSet Norway

Intensive care monitoring

Unknown
16 employees
Biotechnology, Health Care
Compare Apollon vs GlucoSet
Apollon vs
OptiScan Biomedical Corporation
OptiScan Biomedical Corporation United States

Precision Glucose Monitoring for ICU and CCU Care

Series E
1 employees
Biotechnology, Health Care
Compare Apollon vs OptiScan Biomedical Corporation
Apollon vs
Echo Therapeutics
Echo Therapeutics United States

Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) syst...

Post Ipo Debt
8 employees
Biotechnology, Health Care
Compare Apollon vs Echo Therapeutics
View all alternatives

FAQ About Apollon

The wearable that reads your glucose
Apollon was founded in 2021.
Apollon is headquartered in Korea South.
Apollon operates in the following industries: Biotechnology, Health Care, Medical Devices, Autonomous and Sensor Tech, Machine Learning.
Apollon has approximately 40 employees.
Apollon has completed 2 funding rounds, raising a total of $2.30B. The latest funding stage is Seed.
Apollon offers: Development of needle-free continuous glucose monitors, Research and innovation in Raman-based glucose sensing, Integration of optical engineering in wearable medical devices.
Top alternatives and competitors to Apollon include GlucoSet, OptiScan Biomedical Corporation, Echo Therapeutics, DiaMonTech AG, PKvitality. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Apollon and GlucoSet are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Apollon and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy